Articles

Diagnostic testing in myeloid malignancies by next-generation sequencing: recommendations from the Commission Personalised Medicine

BJH - volume 10, issue 6, october 2019

E. Van Valckenborgh PhD, M. Bakkus PhD, E. Boone PhD, A. Camboni MD, PhD, J-P. Defour PhD, B. Denys MD, H. Devos MD, L. Dewispelaere MD, G. Froyen PhD, A. Hébrant PhD, P. Heimann MD, PhD, P. Hermans MD, PhD, E. Heylen PhD, K. Jacobs PhD, F. Lambert MD, M. Le Mercier Apr, PhD, E. Lierman PhD, H. Louagie MD, PhD, B. Maes MD, PhD, M-B. Maes PhD, G. Martens MD, PhD, L. Michaux MD, PhD, F. Nollet PhD, MSc, H.A. Poirel MD, PhD, G. Raicevic PhD, P. Saussoy MD, PhD, T. Tousseyn MD, PhD, M. Van Den Bulcke PhD, P. Vandenberghe MD, PhD, K. Vandepoele PhD, P. Vannuffel PhD, T. Venken PhD, K. Vermeulen PhD

SUMMARY

Molecular diagnostics have an increasing impact on diagnosis, risk stratification and targeted treatment in haemato-oncology. In the framework of a pilot study for the implementation of next-generation sequencing in the Belgian healthcare system, the Commission of Personalised Medicine was founded to give professional and evidence-based advice on the molecular analysis in haemato-oncology. This paper describes its recommendations for NGS analysis in myeloid malignancies. In addition, the minimally required set of genes that must be analysed is defined and algorithms for molecular workflow in myeloid malignancies are proposed.

(BELG J HEMATOL 2019;10(6):241–9)

Read more

O03 LUPUS ANTICOAGULANT HYPOPROTHROMBINAEMIA SYNDROME: A PAEDIATRIC CASE REPORT

BJH - 2019, issue ?, february 2019

S. Vandamme , K. Ver Elst , M-B. Maes PhD, S. Vermeiren

Read more

P13 THE VALUE OF LABORATORY SCREENING VS. CLINICAL JUDGMENT IN HIT DIAGNOSIS: EXPERIENCES IN THREE BELGIAN HOSPITALS

BJH - 2019, issue ?, february 2019

K. Eeckhout , G. Glynis , J. Emmerechts MD, PhD, K. Schatteman , M-B. Maes PhD, E. Bailleul

Read more

P14 PRELIMINARY EVALUATION OF ADAMTS-13 ANTIBODY TESTING

BJH - 2019, issue ?, february 2019

N. Van Den Eede , J. Van Den Bossche , K. Deiteren , R. Malfait MD, M-B. Maes PhD

Read more

P16 HOW TO DEAL WITH SAMPLES WITH ERRORS ON APTT, PT AND FIBRINOGEN DUE TO OPTICAL CLOT DETECTION?

BJH - 2019, issue ?, february 2019

K. Eeckhout , J. Van Den Bossche , K. Deiteren , R. Malfait MD, M-B. Maes PhD

Read more

Myeloid sarcoma or lymphoblastic lymphoma? A closer look at the laboratory diagnosis

BJH - volume 4, issue 3, september 2013

L. Roosens PhD, K. Vermeulen PhD, A. Verlinden MD, H. Devos MD, E. Van Assche , I. Vrelust MD, M-B. Maes PhD, R. Malfait MD

Summary

Although a myeloid sarcoma is a rare form of extramedullary leukaemia, its early diagnosis has been proven to be of utmost importance. Its presence is strongly related to the onset or the presence of systemic bone marrow leukaemia. However, the diagnosis of myeloid sarcoma is not straightforward. In the existing literature, approximately half of the cases of myeloid sarcoma were initially misdiagnosed as lymphoma. The current case reports details on the laboratory diagnosis of myeloid sarcoma in a 25-year old male. The laboratory presentation of myeloid sarcoma and the consecutive steps in order to correctly diagnose myeloid sarcoma using a variety of laboratory techniques including microscopy, flow cytometry and cytogenetics are highlighted.

(BELG J HEMATOL 2013;4(3): 106–109)

Read more
X